SCHEDULE 13G/A: JPMorgan Chase & Co. Discloses 4.4% Passive Stake in Regeneron Pharmaceuticals

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 4.4% beneficial ownership stake in Regeneron Pharmaceuticals, Inc. as of May 30, 2025.

Summary

• JPMorgan Chase & Co. (JPMC) has filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Regeneron Pharmaceuticals, Inc.
• As of May 30, 2025, JPMC beneficially owns an aggregate of 4,742,611 shares of Regeneron's Common Stock.
• This ownership represents 4.4% of the class of securities.
• JPMC holds sole voting power over 4,189,434 shares and shared voting power over 41,470 shares.
• JPMC holds sole dispositive power over 4,698,332 shares and shared dispositive power over 40,965 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Regeneron Pharmaceuticals, Inc.
• JPMC is classified as a parent holding company (HC) for this filing.
• Several subsidiaries of JPMorgan Chase & Co. are identified as having acquired the securities, including J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, and various JPMorgan Asset Management entities.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a passive investment by a major financial institution, JPMorgan Chase & Co., in a prominent biotechnology company, Regeneron Pharmaceuticals. Such filings are routine disclosures for institutional investors holding significant, but non-controlling, stakes in public companies. It reflects continued institutional interest in the pharmaceutical and biotechnology sectors, which are often seen as defensive investments or growth opportunities depending on market conditions and pipeline developments.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can be viewed as a vote of confidence or a routine investment. No direct impact on share price unless the stake is new or significantly changed, which is not explicitly stated as a new stake here.
• Company Management: Awareness of a large, passive institutional holder, but no direct impact on operations or strategy as the stake is not for control purposes.

Key Dates

Keywords

Regeneron Pharmaceuticals, JPMorgan Chase & Co., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology, SEC Filing